US equities
|
SPCX
$159.31
▲+7.79%
META
$697.52
▲+0.47%
NVDA
$221.97
▲+2.54%
MU
$913.67
▲+1.96%
TSLA
$386.47
▲+3.41%
AAPL
$343.99
▲+1.32%
AMD
$552.72
▲+3.36%
GOOGL
$334.76
▼-1.62%
SPCX
$159.31
▲+7.79%
META
$697.52
▲+0.47%
NVDA
$221.97
▲+2.54%
MU
$913.67
▲+1.96%
TSLA
$386.47
▲+3.41%
AAPL
$343.99
▲+1.32%
AMD
$552.72
▲+3.36%
GOOGL
$334.76
▼-1.62%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Dyne Therapeutics, Inc. - Common Stock
(NQ:
DYN
)
16.07
-0.20 (-1.23%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyne Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
July 01, 2025
Via
Benzinga
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
↗
July 01, 2025
Via
Benzinga
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
June 30, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 30, 2025
Via
Benzinga
These stocks are moving in today's after hours session
↗
June 30, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
June 30, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
June 30, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 30, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 26, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 25, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 24, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. – DYN
June 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 20, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
June 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial
↗
June 17, 2025
The updated study will enroll 60 participants and track additional measures like muscle strength, mobility, and patient-reported outcomes.
Via
Stocktwits
Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN
June 17, 2025
From
The DJS Law Group
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
June 17, 2025
Via
Benzinga
Which stocks are moving on Tuesday?
↗
June 17, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via
Chartmill
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday?
↗
June 17, 2025
Dyne updates DYNE-101 trial timeline, reports strong 12-month data, and receives FDA Breakthrough Therapy status for treating DM1.
Via
Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session.
↗
June 17, 2025
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
June 17, 2025
Via
Benzinga
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
June 17, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 16, 2025
Via
Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
↗
June 16, 2025
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
June 16, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
June 05, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 08, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
April 24, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
